Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00304291 · ClinicalTrials.gov registry record · Phase 4
A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)
A Phase 4 study of Neuromyelitis Optica and Myelitis, Transverse, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT00304291: Completed Phase 4 study of Neuromyelitis Optica and Myelitis, Transverse, sponsored by State University of New York at Buffalo.
NCT00304291 is a Phase 4 study of Neuromyelitis Optica and Myelitis, Transverse that has completed, run by State University of New York at Buffalo. The registered enrollment target is 5 participants, below the 513-participant average among 7 other Neuromyelitis Optica trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00304291, a Phase 4 study of Neuromyelitis Optica and Myelitis, Transverse, has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
Neuromyelitis optica (NMO) is a severe demyelinating disease that selectively involves the optic nerves and the spinal cord but usually spares the brain. NMO is considered to have a B cell induced pathogenesis. Mitoxantrone (MITO, Novantrone®), a synthetic anthracenedione approved for worsening relapsing-remitting multiple sclerosis (MS) and secondary progressive MS, has been shown to primarily suppress the humoral response. We conducted a prospective 2-year study to evaluate the benefit of MITO in five relapsing NMO patients.
Conditions Studied
Interventions
- DRUG Mitoxantrone
Study Locations (1)
New York
- Baird Multiple Sclerosis Center - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2001-08 |
| Est. Completion | 2004-05 |
| Phase | Phase 4 |
What the finished NCT00304291 record still lists
NCT00304291 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 513-participant average among 7 other Neuromyelitis Optica trials with a reported enrollment target (99% lower).
The record links to 4 conditions, with Neuromyelitis Optica appearing as the primary indexed condition, and to 1 intervention - of which Mitoxantrone is the first listed.
NCT00304291 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00304291 about?
NCT00304291 is a clinical study titled "A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)". Neuromyelitis optica (NMO) is a severe demyelinating disease that selectively involves the optic nerves and the spinal cord but usually spares the brain. NMO is considered to have a B cell induced pathogenesis. Mitoxantrone (MITO, Novantrone®), a synthetic anthracenedione approved for worsening rela...
What is the current status of trial NCT00304291?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2001-08. Estimated completion is 2004-05.
What conditions does trial NCT00304291 study?
This clinical trial studies the following conditions: Neuromyelitis Optica, Myelitis, Transverse, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS.
What interventions are being tested in trial NCT00304291?
The interventions under investigation include: Mitoxantrone (DRUG).
Who is sponsoring clinical trial NCT00304291?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00304291 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuromyelitis Optica
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder
RECRUITING
-
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
RECRUITING · NA
-
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
ACTIVE NOT RECRUITING
-
Biobank For MS And Other Demyelinating Diseases
ACTIVE NOT RECRUITING
-
High Frequency Impulse Therapy for Neuropathic Pain in NMOSD
COMPLETED · Phase 2
-
An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia